State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, PR China.
Division of Molecular Therapeutics & Formulation, School of Pharmacy, The University of Nottingham, University Park Campus, Nottingham NG7 2RD, UK.
Eur J Med Chem. 2021 Apr 15;216:113316. doi: 10.1016/j.ejmech.2021.113316. Epub 2021 Feb 24.
A series of novel N-benzylbenzamide derivatives were designed and synthesized as tubulin polymerization inhibitors. Among fifty-one target compounds, compound 20b exhibited significant antiproliferative activities with IC values ranging from 12 to 27 nM against several cancer cell lines, and possessed good plasma stability and satisfactory physicochemical properties. Mechanism studies demonstrated that 20b bound to the colchicine binding site and displayed potent anti-vascular activity. Notably, the corresponding disodium phosphate 20b-P exhibited an excellent safety profile with the LD value of 599.7 mg/kg (i.v. injection), meanwhile, it significantly inhibited tumor growth and decreased microvessel density in liver cancer cell H22 allograft mouse model without obvious toxicity. Collectively, 20b and 20b-P are novel promising anti-tubulin agents with more druggable properties and deserve to be further investigated for cancer therapy.
一系列新型 N-苄基苯甲酰胺衍生物被设计并合成作为微管聚合抑制剂。在 51 个目标化合物中,化合物 20b 对几种癌细胞系表现出显著的增殖抑制活性,IC 值范围为 12 至 27 nM,并且具有良好的血浆稳定性和令人满意的物理化学性质。机制研究表明,20b 与秋水仙碱结合位点结合,并表现出很强的抗血管生成活性。值得注意的是,相应的磷酸二氢钠 20b-P 具有优异的安全性,LD 值为 599.7 mg/kg(静脉注射),同时,它显著抑制肝癌细胞 H22 异种移植小鼠模型中的肿瘤生长并降低微血管密度,没有明显的毒性。总的来说,20b 和 20b-P 是具有更多可成药性的新型有前途的抗微管剂,值得进一步研究用于癌症治疗。